Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Results of safety monitoring of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in U.S. children aged 5-17 years

Mao Hu, Hui Lee Wong, Yuhui Feng, Patricia C. Lloyd, Elizabeth R. Smith, Kandace L. Amend, Annemarie Kline, Daniel C. Beachler, Joann F. Gruber, Mahasweta Mitra, John D. Seeger, Charlalynn Harris, Alex Secora, Joyce Obidi, Jing Wang, Jennifer Song, Cheryl N. McMahill-Walraven, Christian Reich, Rowan McEvoy, Rose Do, Yoganand Chillarige, Robin Clifford, Danielle D Cooper, Azadeh Shoaibi, Richard Forshee, Steven A. Anderson
doi: https://doi.org/10.1101/2022.10.28.22281532
Mao Hu
1Acumen LLC, Burlingame, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hui Lee Wong
2US Food and Drug Administration, Silver Spring, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuhui Feng
1Acumen LLC, Burlingame, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia C. Lloyd
2US Food and Drug Administration, Silver Spring, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth R. Smith
1Acumen LLC, Burlingame, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kandace L. Amend
3Optum Epidemiology, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annemarie Kline
4HealthCore, Inc, Wilmington, DE, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel C. Beachler
5CVS Health Clinical Trial Services, Blue Bell, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joann F. Gruber
2US Food and Drug Administration, Silver Spring, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mahasweta Mitra
1Acumen LLC, Burlingame, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John D. Seeger
3Optum Epidemiology, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlalynn Harris
4HealthCore, Inc, Wilmington, DE, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Secora
6IQVIA, Falls Church, VA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joyce Obidi
2US Food and Drug Administration, Silver Spring, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Wang
1Acumen LLC, Burlingame, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Song
3Optum Epidemiology, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheryl N. McMahill-Walraven
4HealthCore, Inc, Wilmington, DE, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Reich
6IQVIA, Falls Church, VA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rowan McEvoy
1Acumen LLC, Burlingame, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rose Do
1Acumen LLC, Burlingame, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoganand Chillarige
1Acumen LLC, Burlingame, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robin Clifford
3Optum Epidemiology, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Danielle D Cooper
4HealthCore, Inc, Wilmington, DE, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Azadeh Shoaibi
2US Food and Drug Administration, Silver Spring, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Forshee
2US Food and Drug Administration, Silver Spring, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven A. Anderson
2US Food and Drug Administration, Silver Spring, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: steven.anderson@fda.hhs.gov
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance Active monitoring of health outcomes following COVID-19 vaccination offers early detection of rare outcomes that may not be identified in pre-licensure trials.

Objective To conduct near-real time monitoring of health outcomes following BNT162b2 COVID-19 vaccination in the U.S. pediatric population aged 5-17 years.

Design We conducted rapid cycle analysis of 20 pre-specified health outcomes, 13 of which underwent sequential testing and 7 of which were monitored descriptively within a cohort of vaccinated individuals. We tested for increased risk of each health outcome following vaccination compared to a historical baseline, while adjusting for repeated looks at the data as well as claims processing delay.

Setting This is a population-based study in three large commercial claims databases conducted under the U.S. FDA public health surveillance mandate.

Participants The study included over 3 million enrollees aged 5-17 years with BNT162b2 COVID-19 vaccination through mid-2022 in three commercial claims databases. We required continuous enrollment in a medical health insurance plan from the start of an outcome-specific clean window to the COVID-19 vaccination.

Exposure Exposure was defined as receipt of a BNT162b2 COVID-19 vaccine dose. The primary analysis assessed primary series doses together (Dose 1 + Dose 2), and dose-specific secondary analyses were conducted. Follow up time was censored for death, disenrollment, end of risk window, end of study period, or a subsequent vaccine dose.

Main Outcome(s) and Measure(s) We monitored 20 pre-specified health outcomes. We performed descriptive monitoring for all outcomes and sequential testing for 13 outcomes.

Results Among 13 health outcomes evaluated by sequential testing, 12 did not meet the threshold for a statistical signal in any of the three databases. In our primary analysis, myocarditis/pericarditis signaled following primary series vaccination with BNT162b2 in ages 12-17 years across all three databases.

Conclusions and Relevance Consistent with published literature, our near-real time monitoring identified a signal for only myocarditis/pericarditis following BNT162b2 COVID-19 vaccination in children aged 12-17 years. This method is intended for early detection of safety signals. Our results are reassuring of the safety of the vaccine, and the potential benefits of vaccination outweigh the risks.

Question Did active monitoring detect potentially elevated risk of health outcomes following BNT162b2 COVID-19 vaccination in the U.S. pediatric population aged 5-17 years?

Findings Twelve of 13 health outcomes did not meet the safety signal threshold following BNT162b2 COVID-19 vaccination in three large commercial claims databases using near real-time monitoring. Myocarditis/pericarditis met the statistical threshold for a signal following primary series vaccination in ages 12-17 years.

Meaning Results from near-real time monitoring of health outcomes following BNT162b2 COVID-19 vaccination provide additional reassuring evidence of vaccine safety in the pediatric population. The myocarditis/pericarditis signal is consistent with current evidence and is being further evaluated.

Competing Interest Statement

Annemarie Kline and Cheryl McMahill-Walraven worked on grants, subcontracts, or contracts from Harvard Pilgrim Health Care Institute, Brown University (National Institute on Aging/ IMPACT Collaboratory), Reagan Udall Foundation for the FDA, Academy of Managed Care pharmacy's Biologics and Biosimilar Collective Intelligence Consortium (BBCIC), TherapeuticsMD, Reachnet (Louisiana Public Health Institute), IQVIA, Pfizer, Healthcore, and Patient Centered Outcomes Research Institute as employees of CVS Health and report stock or stock options from CVS Health; Danielle Cooper worked on grants, subcontracts, or contracts from Harvard Pilgrim Health Care Institute, Brown University (National Institute on Aging/ IMPACT Collaboratory), Reagan Udall Foundation for the FDA, Academy of Managed Care pharmacy's Biologics and Biosimilar Collective Intelligence Consortium (BBCIC), TherapeuticsMD, Reachnet (Louisiana Public Health Institute), IQVIA, Pfizer, Healthcore, and Westat as an employee of CVS Health and reports stock or stock option from CVS Health; Charlalynn Harris received grants or contracts from Harvard Pilgrim Health Care Institute, Reagan Udall Foundation for the FDA, and Academy of Managed Care pharmacy's Biologics and Biosimilar Collective Intelligence Consortium (BBCIC) as an employee of CVS Health and reports stock or stock options in CVS Health; Robin Clifford and John Seeger report stock or stock options in UnitedHealth Group; Daniel Beachler is an employee of HealthCore, Inc. who has previously contracted with Pfizer Inc. for separate projects. No other authors report relevant disclosures.

Funding Statement

The US Food and Drug Administration provided funding for this study and contributed as follows: led the design of the study, interpretation of the results, writing of the manuscript, decision to submit, and made contributions to the coordination of data collection and analysis of the data.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

We conducted this study within the Biologics Effectiveness and Safety (BEST) Initiative. FDA Amendments Act of 2007 required that FDA develop a national electronic system for monitoring safety of FDA-regulated medical products. FDA built the Sentinel Initiative in response to the congressional requirement, and the BEST Initiative commenced as a Center for Biologics Evaluation and Research (CBER) component of Sentinel. The Office of Human Research Protection (OHRP) determined that the regulations OHRP administers (45 CFR part 46) do not apply to the activities that are included in the FDA's Sentinel Initiative.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The study protocol was publicly posted as referenced in the manuscript before data analyses and related documents can be made available where needed, by contacting the corresponding author. De-identified participant data will not be shared without approval from the data partners.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted October 30, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Results of safety monitoring of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in U.S. children aged 5-17 years
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Results of safety monitoring of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in U.S. children aged 5-17 years
Mao Hu, Hui Lee Wong, Yuhui Feng, Patricia C. Lloyd, Elizabeth R. Smith, Kandace L. Amend, Annemarie Kline, Daniel C. Beachler, Joann F. Gruber, Mahasweta Mitra, John D. Seeger, Charlalynn Harris, Alex Secora, Joyce Obidi, Jing Wang, Jennifer Song, Cheryl N. McMahill-Walraven, Christian Reich, Rowan McEvoy, Rose Do, Yoganand Chillarige, Robin Clifford, Danielle D Cooper, Azadeh Shoaibi, Richard Forshee, Steven A. Anderson
medRxiv 2022.10.28.22281532; doi: https://doi.org/10.1101/2022.10.28.22281532
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Results of safety monitoring of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in U.S. children aged 5-17 years
Mao Hu, Hui Lee Wong, Yuhui Feng, Patricia C. Lloyd, Elizabeth R. Smith, Kandace L. Amend, Annemarie Kline, Daniel C. Beachler, Joann F. Gruber, Mahasweta Mitra, John D. Seeger, Charlalynn Harris, Alex Secora, Joyce Obidi, Jing Wang, Jennifer Song, Cheryl N. McMahill-Walraven, Christian Reich, Rowan McEvoy, Rose Do, Yoganand Chillarige, Robin Clifford, Danielle D Cooper, Azadeh Shoaibi, Richard Forshee, Steven A. Anderson
medRxiv 2022.10.28.22281532; doi: https://doi.org/10.1101/2022.10.28.22281532

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pediatrics
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1099)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9778)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2314)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1563)
  • Health Policy (737)
  • Health Systems and Quality Improvement (605)
  • Hematology (238)
  • HIV/AIDS (505)
  • Infectious Diseases (except HIV/AIDS) (11653)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (238)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2146)
  • Nursing (134)
  • Nutrition (338)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1183)
  • Ophthalmology (365)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (147)
  • Palliative Medicine (50)
  • Pathology (312)
  • Pediatrics (697)
  • Pharmacology and Therapeutics (301)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2186)
  • Public and Global Health (4668)
  • Radiology and Imaging (781)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)